Two pediatric cases of multisystem inflammatory-like syndrome following COVID-19 vaccination

Area of Science:

• Pediatric infectious diseases
• Vaccine safety and immunology

Background:

• Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition linked to SARS-CoV-2 infection.
• Concerns exist regarding potential adverse events following COVID-19 vaccination, including cardiac conditions like myocarditis.

Purpose of the Study:

• To report two cases of pediatric patients who presented with MIS-C-like symptoms shortly after receiving the Pfizer-BNT162b2 COVID-19 vaccine.
• To explore a potential association between the Pfizer-BNT162b2 vaccine and the development of MIS-C in children.

Main Methods:

• Case report describing two pediatric patients.
• Clinical and laboratory features suggestive of MIS-C were analyzed.
• Temporal relationship between vaccination and symptom onset was examined.

Main Results:

• Both patients developed MIS-C-like symptoms within days of their first Pfizer-BNT162b2 vaccine dose.
• One patient received treatment with corticosteroids and immunoglobulin, with a favorable outcome.
• Both patients experienced a positive clinical outcome.

Conclusions:

• These cases suggest a possible association between the Pfizer-BNT162b2 COVID-19 vaccine and the occurrence of MIS-C in pediatric populations.
• Further investigation is warranted to understand this potential link and inform vaccination guidelines.